Literature DB >> 16136386

Gynecologic Cancers in Lynch Syndrome/HNPCC.

Karen H Lu1, Russell R Broaddus.   

Abstract

Recent studies have estimated that the lifetime risk of endometrial cancer in women with Lynch syndrome/hereditary non-polyposis colorectal cancer syndrome (Lynch/HNPCC) is 40-60%. This risk equals or exceeds their risk for colon cancer. While much research has been done to define the natural history and molecular features of Lynch/HNPCC associated colon cancer, there has been considerably less research defining Lynch/HNPCC associated endometrial cancer. This article will review current information regarding the clinico-pathologic features of Lynch/HNPCC associated endometrial cancer. In addition, current consensus guidelines for endometrial cancer screening and prevention for women with Lynch/HNPCC will be discussed. Given the increased risk of multiple cancers, changing the name of this syndrome from hereditary non-polyposis colorectal cancer syndrome to Lynch Syndrome may benefit both patients and clinicians. Clinicians caring for women with Lynch/HNPCC may stress colon cancer screening and prevention without reviewing endometrial cancer risks and symptoms or screening and prevention options. Perhaps more importantly, women with Lynch/HNPCC may focus on colon cancer risks and lack understanding of endometrial cancer risks. With increasing evidence that women with Lynch/HNPCC have significant risks for both colon and endometrial cancers, we believe a multi-disciplinary approach to the management of these individuals is crucial.

Entities:  

Mesh:

Year:  2005        PMID: 16136386     DOI: 10.1007/s10689-005-1838-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  28 in total

1.  Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium.

Authors:  A L Millar; T Pal; L Madlensky; C Sherman; L Temple; A Mitri; H Cheng; V Marcus; S Gallinger; M Redston; B Bapat; S Narod
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

Review 2.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium.

Authors:  W Burke; G Petersen; P Lynch; J Botkin; M Daly; J Garber; M J Kahn; A McTiernan; K Offit; E Thomson; C Varricchio
Journal:  JAMA       Date:  1997-03-19       Impact factor: 56.272

3.  The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis.

Authors:  F P Dijkhuizen; B W Mol; H A Brölmann; A P Heintz
Journal:  Cancer       Date:  2000-10-15       Impact factor: 6.860

4.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

5.  The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer.

Authors:  H F Vasen; P Watson; J P Mecklin; J R Jass; J S Green; T Nomizu; H Müller; H T Lynch
Journal:  Anticancer Res       Date:  1994 Jul-Aug       Impact factor: 2.480

6.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

Authors:  Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

7.  Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability.

Authors:  Shannon A Kuismanen; Anu-Liisa Moisio; Pascal Schweizer; Kaspar Truninger; Reijo Salovaara; Johanna Arola; Ralf Butzow; Josef Jiricny; Minna Nyström-Lahti; Päivi Peltomäki
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

8.  Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation.

Authors:  Jane Green; Mary O'Driscoll; Adam Barnes; Eamonn R Maher; Peter Bridge; Keith Shields; Patrick S Parfrey
Journal:  Dis Colon Rectum       Date:  2002-09       Impact factor: 4.585

9.  The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer.

Authors:  P Watson; H F Vasen; J P Mecklin; H Järvinen; H T Lynch
Journal:  Am J Med       Date:  1994-06       Impact factor: 4.965

10.  Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members.

Authors:  P Watson; K M Lin; M A Rodriguez-Bigas; T Smyrk; S Lemon; M Shashidharan; B Franklin; B Karr; A Thorson; H T Lynch
Journal:  Cancer       Date:  1998-07-15       Impact factor: 6.860

View more
  17 in total

Review 1.  Molecular pathogenesis of endometrial and ovarian cancer.

Authors:  Melissa A Merritt; Daniel W Cramer
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

2.  One case of endometrial cancer occurrence: Over 10 years after colon cancer in Lynch family.

Authors:  Jee Yeon Lee; Hyun Joo Kim; Eun Hee Lee; Hyoun Wook Lee; Jong-Won Kim; Min Kyu Kim
Journal:  Obstet Gynecol Sci       Date:  2013-11-15

3.  Testing women with endometrial cancer to detect Lynch syndrome.

Authors:  Janice S Kwon; Jenna L Scott; C Blake Gilks; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

4.  Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.

Authors:  Masataka Adachi; Kouji Banno; Megumi Yanokura; Miho Iida; Kanako Nakamura; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Arisa Ueki; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-11-20

5.  Self administered screening for hereditary cancers in conjunction with mammography and ultrasound.

Authors:  Charles H McDonnell; David J Seidenwurm; Diana E McDonnell; Kristie A Bobolis
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

6.  Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil.

Authors:  Silvia Liliana Cossio; Patricia Koehler-Santos; Suzana Arenhart Pessini; Heleuza Mónego; Maria Isabel Edelweiss; Luise Meurer; Abdellatif Errami; Jordy Coffa; Hugo Bock; Maria Luiza Saraiva-Pereira; Patricia Ashton-Prolla; João Carlos Prolla
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

7.  Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome.

Authors:  Marilyn Huang; Bojana Djordjevic; Melinda S Yates; Diana Urbauer; Charlotte Sun; Jennifer Burzawa; Molly Daniels; Shannon N Westin; Russell Broaddus; Karen Lu
Journal:  Cancer       Date:  2013-06-12       Impact factor: 6.860

8.  The extracolonic cancer spectrum in females with the common 'South African' hMLH1 c.C1528T mutation.

Authors:  Maria M Blokhuis; Paul A Goldberg; G Elize Pietersen; Ursula Algar; A Alvera Vorster; Dhiren Govender; Raj S Ramesar
Journal:  Fam Cancer       Date:  2007-11-30       Impact factor: 2.375

9.  Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.

Authors:  Anne M Mills; Sofia Liou; James M Ford; Jonathan S Berek; Reetesh K Pai; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2014-11       Impact factor: 6.394

10.  Strategies for endometrial screening in the Lynch syndrome population: a patient acceptability study.

Authors:  K Elmasry; A J Davies; D G Evans; M N Seif; K Reynolds
Journal:  Fam Cancer       Date:  2009-06-13       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.